Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet. 2009 Nov 28;374(9704):1849-56. doi: 10.1016/S0140-6736(09)61834-1.

Interventions for muscular dystrophy: molecular medicines entering the clinic.

Author information

  • 1Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK. kate.bushby@ncl.ac.uk

Abstract

Muscular dystrophies are individually rare genetic disorders that cause much chronic disability, affecting young children and adults. In the past 20 years, more than 30 genetic types of muscular dystrophy have been defined. During this time, precise diagnosis, genetic counselling, and medical management have improved. These advances in medical practice have occurred while definitive therapies based on an improved knowledge of disease pathogenesis are awaited. A wide range of therapeutic options have been tested in animal models, and some are being tested in clinical trials. Various therapeutic targets are being investigated, from personalised medicines targeting specific mutations and drugs targeting cellular pathways to gene-based and cell-based therapies.

PMID:
19944865
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk